Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape

28 Mar 2025

Abstract excerpt

Most previously authorized clinical antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have lost neutralizing activity to recent variants due to rapid viral evolution. To mitigate such escape, we preemptively enhance AZD3152, an antibody authorized for prophylaxis in immunocompromised individuals. Using deep mutational scanning (DMS) on the SARS-CoV-2 antigen, we identify AZD3152...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40153503
DOI: 10.1126/sciadv.adu0718

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escapePMID 40153503Read ↗

Evaluating SARS-CoV-2 Antibody Resilience via Prediction and Design of Escape Viral VariantsSemantic proximity Read ↗

Broadening a SARS-CoV-1–neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolutionSemantic proximity Read ↗

High-throughput ML-guided design of diverse single-domain antibodies against SARS-CoV-2Semantic proximity Read ↗

Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2Semantic proximity Read ↗

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariantsSemantic proximity Read ↗

Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizersSemantic proximity Read ↗

Deep learning-guided selection of antibody therapies with enhanced resistance to current and prospective SARS-CoV-2 Omicron variantsSemantic proximity Read ↗

Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralizationSemantic proximity Read ↗

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escapeSemantic proximity Read ↗

Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron VariantsSemantic proximity Read ↗

Structural and mutational analyses define distinct molecular routes to broad SARS-CoV-2 receptor-binding domain recognitionSemantic proximity Read ↗

Antibody drugs targeting SARS-CoV-2: Time for a rethink?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.